Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.42)
# 351
Out of 5,113 analysts
238
Total ratings
44.91%
Success rate
28.26%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals | Maintains: Overweight | $11 → $19 | $8.99 | +111.35% | 2 | Jan 15, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | $21 → $15 | $14.29 | +1.47% | 8 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $24.44 | +96.40% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $10.94 | +119.38% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $7.54 | +151.99% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $8.93 | +168.76% | 4 | Nov 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $32 → $38 | $37.25 | +2.01% | 9 | Nov 5, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $132 → $153 | $82.21 | +86.11% | 9 | Oct 17, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Overweight | $46 → $63 | $49.52 | +27.22% | 4 | Sep 30, 2025 | |
| QURE uniQure | Maintains: Overweight | $47 → $80 | $24.37 | +228.27% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $24.62 | +326.48% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $75.49 | +56.31% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $70.29 | +5.28% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $6.57 | +143.53% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $23.52 | +27.55% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $22.17 | +265.36% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.76 | +47.06% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $43.16 | +184.99% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $3.70 | +2,332.43% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.47 | +1,383.37% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $16.58 | +50.78% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $26.23 | +155.43% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $3.47 | +389.91% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $3.42 | +133.92% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.43 | +669.23% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.11 | +252.25% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $1.07 | +1,208.41% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.03 | +1,162.14% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.29 | +1,527.91% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.63 | +268.10% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.50 | +3,922.53% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $7.32 | +214.21% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $1.02 | +88,135.29% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $25.53 | +1,466.78% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $2.28 | +3,628.07% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.79 | +2,550.96% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.74 | +10,244.83% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.59 | +591.82% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.80 | +3,233.33% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.08 | +8,248.79% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.85 | +298,124.85% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $6.95 | +43,641.01% | 1 | Jan 9, 2020 |
Eupraxia Pharmaceuticals
Jan 15, 2026
Maintains: Overweight
Price Target: $11 → $19
Current: $8.99
Upside: +111.35%
Amicus Therapeutics
Dec 19, 2025
Downgrades: Neutral
Price Target: $21 → $15
Current: $14.29
Upside: +1.47%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $24.44
Upside: +96.40%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $10.94
Upside: +119.38%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $7.54
Upside: +151.99%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $8.93
Upside: +168.76%
Rigel Pharmaceuticals
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $37.25
Upside: +2.01%
Disc Medicine
Oct 17, 2025
Maintains: Overweight
Price Target: $132 → $153
Current: $82.21
Upside: +86.11%
Supernus Pharmaceuticals
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $49.52
Upside: +27.22%
uniQure
Sep 25, 2025
Maintains: Overweight
Price Target: $47 → $80
Current: $24.37
Upside: +228.27%
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $24.62
Upside: +326.48%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $75.49
Upside: +56.31%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $70.29
Upside: +5.28%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $6.57
Upside: +143.53%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $23.52
Upside: +27.55%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $22.17
Upside: +265.36%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $4.76
Upside: +47.06%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $43.16
Upside: +184.99%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $3.70
Upside: +2,332.43%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.47
Upside: +1,383.37%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $16.58
Upside: +50.78%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $26.23
Upside: +155.43%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $3.47
Upside: +389.91%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $3.42
Upside: +133.92%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.43
Upside: +669.23%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.11
Upside: +252.25%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $1.07
Upside: +1,208.41%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.03
Upside: +1,162.14%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.29
Upside: +1,527.91%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.63
Upside: +268.10%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.50
Upside: +3,922.53%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $7.32
Upside: +214.21%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $1.02
Upside: +88,135.29%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $25.53
Upside: +1,466.78%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.28
Upside: +3,628.07%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.79
Upside: +2,550.96%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.74
Upside: +10,244.83%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.59
Upside: +591.82%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.80
Upside: +3,233.33%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.08
Upside: +8,248.79%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.85
Upside: +298,124.85%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $6.95
Upside: +43,641.01%